All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub

Brought to you by Scientific Education Support

Scientific Education Support

The Multiple Myeloma Hub is an independent medical education platform, sponsored by AbbVie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My Multiple Myeloma Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View multiple myeloma content recommended for you

EBMT 2022

Share:

May 9, 2022

X post image

13 Sept 2022

🎥 Have you seen this?
During the #EBMT22, the MM Hub was pleased to speak to @MorieGertz, @MayoClinic. We asked, In the era of upfront quadruplets, is there still a role for tandem transplant? 👇 #mmsm #myeloma

https://t.co/taFSTmm0jJ

X post image

10 Sept 2022

Have you seen this❓
@mbeksac56 discussed a new scoring system for risk of early relapse in patients with #myeloma at #EBMT22. Find the write-up here, with a closer look at high-risk patients.

👉 https://t.co/dGHB5elAXf 👈

#mmsm #bmtsm @EBMT

X post image

8 Sept 2022

Have you seen this❓
🌍 A global perspective on current barriers and future directions for access to #CARTcells was provided during the latest @EBMT congress. Read more in our article on the MM Hub

👉 https://t.co/H032vqzHnX 👈

#EBMT22 #bmtsm #mmsm

X post image

3 Sept 2022

Have you seen this? 🎥
During #EBMT22, the Multiple Myeloma Hub was pleased to speak to @ninashah33, UCSF. We asked, What factors correlate with a better response to BCMA-directed CAR T-cell products?

👉 https://t.co/ZnlvNq28t4 👈

#mmsm #myeloma

X post image

31 Aug 2022

Have you watched this❓
🎥 During #EBMT22, the MM Hub was pleased to speak to Elena Zamagni, University of Bologna. We asked, How can MRD assessment help when treating patients with high-risk MM after transplantation?

👉 https://t.co/2fbrjX7sHj 👈

#mmsm #myeloma

X post image

25 Jun 2022

🎥 Did you see this from #EBMT22

The MM Hub was pleased to speak to @MorieGertz, @MayoClinic. We asked, In the era of upfront quadruplets, is there still a role for tandem transplant?

👉 https://t.co/taFSTmDBbh 👈

#MMSM #multiplemyeloma #myeloma

X post image

23 Jun 2022

Have you read this yet❓

@mbeksac56 discussed a new scoring system for risk of early relapse in patients with #myeloma at #EBMT22. 📝 Find the write-up here, with a closer look at high-risk patients. 👇

👉 https://t.co/dGHB5e3rJ7 👈

#mmsm #bmtsm @EBMT

X post image

17 May 2022

🎥 During the #EBMT22, the MM Hub was pleased to speak to @MorieGertz, @MayoClinic. We asked, In the era of upfront quadruplets, is there still a role for tandem transplant? 👇 #mmsm #myeloma

https://t.co/taFSTmm0jJ

X post image

11 May 2022

🎥 Did you miss this video from @mbeksac56 ❓

Watch the full video on the MM Hub 👇 #EBMT22 #mmsm
👉 https://t.co/9btWSkLREo 👈

X post image

28 Apr 2022

@mbeksac56 discussed a new scoring system for risk of early relapse in patients with #myeloma at #EBMT22. 📝 Find the write-up here, with a closer look at high-risk patients. 👇

👉 https://t.co/dGHB5el37H 👈

#mmsm #bmtsm @EBMT

X post image

26 Apr 2022

🌍 A global perspective on current barriers and future directions for access to #CARTcells was provided during the latest @EBMT congress. Read more in our article on the MM Hub 👇

👉 https://t.co/H032vqzHnX 👈

#EBMT22 #bmtsm #mmsm

X post image

21 Apr 2022

🎥 During #EBMT22, the Multiple Myeloma Hub was pleased to speak to @ninashah33, UCSF. We asked, What factors correlate with a better response to BCMA-directed CAR T-cell products?

👉 https://t.co/ZnlvNqjJkC 👈

#mmsm #myeloma

X post image

11 Apr 2022

🎥 During #EBMT22, the MM Hub was pleased to speak to Elena Zamagni, University of Bologna. We asked, How can MRD assessment help when treating patients with high-risk MM after transplantation? 🤔👀

👉 https://t.co/2fbrjX7sHj 👈

#mmsm #myeloma

X post image

29 Mar 2022

We are pleased to attend and cover #EBMT22 this year. You can find all of our tweets in this Twitter Moment 💻
https://t.co/WVYYN5oHY9

X post image

23 Mar 2022

That’s the end of our coverage for the EBMT 48th Annual Meeting!

We hope you’ve enjoyed following EBMT live congress updates with us, from key points, interviews and more.

Keep an eye out for post-congress coverage of EBMT highlights and important topics.

#EBMT22

X post image

23 Mar 2022

➡️Presented by @JeffAuletta #mmsm #EBMT22

X post image

23 Mar 2022

CONGRESS | #EBMT22 | P. Stepensky, Hadassah Medical Center, presents phase I results of locally developed anti-BCMA product in R/R #myeloma
-Heavily treated #myeloma pts including #amyloidosis
-ORR: 71.4%
-Manageable safety, no ICANS reported
-Long-term follow-up is needed
#mmsm

X post image

23 Mar 2022

CONGRESS|#EBMT22|L. Wang,The First Affiliated Hospital @ZJU_China, presents study results on risk factors of prolonged cytopenia after #CARTcell therapy
-↑ CRS grade
-↑ levels of cytokines inc. IL-6, -10, IFN-γ
-CD4/CD8 ratio of CAR T-cells
-Baseline hematopoietic fx
#mmsm

X post image

22 Mar 2022

That’s the end of our coverage for Day 4 of the EBMT 48th Annual Meeting!

EBMT is coming to an end tomorrow, be sure to come back and catch all the final key insights, topics and interviews our medical education hubs will be covering virtually! 💻

#EBMT22

X post image

22 Mar 2022

CONGRESS|#EBMT22|Francesca Gay,@unito, talked on post-transplant MRD negativity in #myeloma. Quadruplet ind/cons with anti-CD38 and ASCT improve the rate of MRD neg. High-risk pts lose MRD- status over time and she says MRD-driven treatment approaches may be needed.#mmsm

X post image

22 Mar 2022

CONGRESS | #EBMT22 | Access to cellular therapy | Nelson Hamerschlak, @hosp_einstein, provided insight from Latin America Perspective. He emphasizes the high cost of CAR T-cell therapies limits access. #mmsm @LABMT2 @ASTCT @CIBMTR @TheEBMT

X post image

22 Mar 2022

CONGRESS|#EBMT22|Access to cellular therapy| Shinichiro Okamoto, Keio University School of Medicine, shares Asian perspective in access issues. #mmsm
Factors include:
- Financial constraints of patients
- Insufficient state funding
- Inadequate lab infrastructure
- Regulations

X post image

22 Mar 2022

CONGRESS | #EBMT22 | He shares possible strategies including patient resources, inclusive research and social policies to improve access and outcomes in ethnically diverse patients. #mmsm

X post image

22 Mar 2022

CONGRESS | #EBMT22 | Jeffery Auletta discusses disparities by race, ethnicity and region in access to and outcomes with cellular therapy from @CIBMTR perspective.
The use of CAR T therapy is mostly in non-Hispanic white patients. Barriers needs to be addressed. THREAD👇
#mmsm

X post image

21 Mar 2022

That’s the end of our coverage for Day 3 of the EBMT 48th Annual Meeting!

Stick around for more key points, interviews and topics coming tomorrow! 🗣

#EBMT22

X post image

21 Mar 2022

CONGRESS | #EBMT22 | Nurse's How Do I best support MM patients in my practice? | Matthias Hellberg-Naegele focuses on managing side effects by drug class and provides recommendations to manage peripheral neuropathy. #MyelomaAwarenessMonth #MyelomaActionMonth #mmsm

X post image

21 Mar 2022

CONGRESS | #EBMT22 | She highlights it is important to inform pts, keep talking about these symptoms, and listen to caregivers/family #MMActionMonth

X post image

21 Mar 2022

CONGRESS | #EBMT22 | Maaike de Ruijter, @amsterdamumc discusses how nurses can help #myeloma pts in fatigue, memory loss and psychological wellbeing & provides useful tools. She says it is crucial to ASK pts about these symptoms. #MyelomaAwarenessMonth #MyelomaActionMonth #mmsm👇

X post image

21 Mar 2022

CONGRESS | #EBMT22 | Nicolaus Kröger
@UKEHamburg touched the role of allo-SCT in #myeloma. Long-term follow-up is needed for graft vs myeloma effect & possible strategies exist to improve outcomes, e.g. prophylactic DLI, GvHD prophylaxis, less toxic conditioning regimen. #mmsm

X post image

21 Mar 2022

CONGRESS|#EBMT22|Roman Hájek, University Hospital Ostrava, discussed the position of CAR T and ASCT in ND #myeloma. CAR T now supplements ASCT in consolidation, optimal position yet to be evaluated. New endpoints needed in trials: sustained MRD neg & treatment-free window. #mmsm

X post image

21 Mar 2022

CONGRESS | #EBMT22 | @mbeksac56, @AnkaraUni_en discussed modern standard treatment vs. ASCT in ND #myeloma pts. She suggests ASCT added to consolidation was associated with better outcomes in multiple studies, including pts with high-risk #myeloma.
#mmsm

X post image

21 Mar 2022

CONGRESS|#EBMT22|L. Garderet, @HopPitieSalpe reported the first results of WAUSTIM study analysing AHCT outcomes of #myeloma pts worldwide. Differences were notable in transplant activity and pts characteristics.
1-year NRM: 1-2%, 1-year relapse: 16%, OS at 84 months: 56%
#mmsm

X post image

21 Mar 2022

CONGRESS | #EBMT22 | @mbeksac56, @AnkaraUni_en explained a novel @TheEBMT early failure score after transplant #myeloma, which was able to identify pts at high risk of relapse with easily available variables of ISS, disease status and PS at AHCT & was predictive of survival #mmsm

X post image

21 Mar 2022

CONGRESS | #EBMT22 | Guldane Cengiz Seval, @AnkaraUni_en, reported real-world data of post-induction undetectable MRD in marrow and graft in pts with #myeloma. gMRD was correlated with mMRD & PFS, had predictive value for response. MRD assessment may be possible in grafts. #mmsm

X post image

21 Mar 2022

Its Day 3 of EBMT!

Multiple Myeloma coverage

The @MM hub will be covering:

- OS01 Oral session 1: Lymphoma, CLL, and multiple myeloma

#EBMT22

X post image

20 Mar 2022

That’s the end of our coverage for Day 2 of the EBMT 48th Annual Meeting!

Keep an eye on our socials for live updates throughout the congress! 🗣

Stay tuned for day 3…👩‍🏫

#EBMT22

X post image

20 Mar 2022

CONGRESS|#EBMT22 | GMMG Symposium | Stefan Schönland, @uniklinik_hd gave a talk on AL #amyloidosis. Early diagnosis is crucial. Daratumumab is highly effective, clonal and renal factors predict outcomes. Clonal and organ biomarkers needed to predict hematologic progression.#mmsm

X post image

20 Mar 2022

CONGRESS| #EBMT22 |GMMG Symposium| Maximilian Merz, @UniLeipzig, covered transplant-ineligible #myeloma pts & compared MAIA and ALCYONE trials. Kidney function impacts outcomes, QoL is important. Early use of novel agents can be considered but financial aspect is a concern. #mmsm

X post image

20 Mar 2022

CONGRESS | #EBMT22 | GMMG Symposium | Katja Weisel, @UKEHamburg, summarized options in treating high-risk #myeloma. Therapeutic challenge remains and early implementation of novel concepts is crucial in patients with high-risk #myeloma. #mmsm

X post image

20 Mar 2022

CONGRESS | #EBMT22 | GMMG Symposium | Marc Raab, @uniklinik_hd, discussed options in relapsed/refractory #myeloma. Several combination approaches used in the first line have improved outcomes; however, the challenge is multi-refractory #myeloma in subsequent lines. #mmsm

X post image

20 Mar 2022

CONGRESS | #EBMT22 | GMMG Symposium | Hartmut Goldschmidt @uniklinik_hd, provided an overview of mAbs in treating #myeloma. Double or triple comb of CD38, CD19 and BCMA or evaluating CD19 in early phase may be considered in the future. #mmsm

X post image

20 Mar 2022

CONGRESS | #EBMT22 | GMMG Symposium | Christof Scheid, @UniCologne, discussed cellular therapy incl. allo- and auto-SCT and CAR T therapy in treating #myeloma. Next steps for CAR T therapy include evaluation in earlier lines, front-line setting and improve manufacturing steps.

X post image

20 Mar 2022

Its Day 2 of EBMT!

Multiple Myeloma coverage

The @MM hub will be covering:

- GMMG Symposium

#EBMT22
#congressupdates #medicaleducation #cancerawareness

X post image

19 Mar 2022

That’s the end of our coverage for Day 1 of the EBMT 48th Annual Meeting!

Remember to follow our account for live updates throughout the congress! 🗣

#EBMT22

X post image

19 Mar 2022

It’s Day 1 of EBMT!

Multiple Myeloma coverage

The @MM hub will be covering:

- Conditioning Regimens

- CAR-based Cellular Therapy – Clinical

#congressupdates #medicaleducation #cancerawareness #EBMT22

X post image

16 Mar 2022

3 days to go until the 48th Annual Meeting of the EBMT! Are you ready?

Follow our hub on Twitter on March 19–23 to stay up to date on interviews, key insights, and more!

#congressupdates #medicaleducation #cancerawareness #EBMT22

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EBMT 2022 European Society for Blood and Marrow Transplantation

Your opinion matters

Regarding bispecific antibodies for multiple myeloma, which of the following do you consider the biggest hurdle for patients and caregivers?

Newsletter

Subscribe to get the best content delivered to your inbox